Compare Novartis AG (NVS) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Clear Secure Inc — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Clear Secure Inc trades at $43.36 (market cap $4.39B). The key difference: Novartis AG is far larger — about 62.4× Clear Secure Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Clear Secure Inc for 19 Days on average.
| NVS | YOU | |
|---|---|---|
Market Cap | $274.00B | $4.39B |
Volume | 1,852,137 | 1,899,845 |
Sector | Health | Technology |
52-Week High | $168.62 | $62.36 |
52-Week Low | $121.80 | $29.61 |
Typical Hold Time | 82 Days | 19 Days |
Enterprise Value | $315.32B | $3.54B |
Dividend Yield | 3.31% | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Clear Secure (YOU) trades at $42.58, up 2.6% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 27% revenue growth in Q2 2026, beating earnings estimates, and robust profitability margins. Recent partnership with CrowdStrike and corporate membership launch highlight growth initiatives. Analyst consensus is mixed with a $61.40 price target representing 44% upside potential.
The stock presents growth potential driven by expanding membership base and enterprise partnerships, but faces risks from competitive pressures and potential execution challenges. Current valuation at 28.77 P/E appears reasonable given growth trajectory, though technical indicators show some overbought conditions that may limit near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
